<p><strong>Natural Alternatives International, Inc.</strong>（纳斯达克代码：NAII）的股东们会很高兴地看到，股价在过去一个月表现出色，上涨了 35%，并从之前的疲软中恢复过来。不幸的是，过去一个月的涨幅对过去一年的损失几乎没有帮助，股票在此期间仍然下跌了 15%。</p>
<p>即使在如此大幅的价格上涨之后，如果你认为 Natural Alternatives International 是一只具有良好投资前景的股票，考虑到美国个人产品行业中几乎一半的公司市销率（&#34;P/S&#34;）超过 1 倍，市销率为 0.2 倍也是可以理解的。然而，我们需要更深入地探讨，以确定是否有合理的依据来解释较低的市销率。</p>
<p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
<p>查看我们对 Natural Alternatives International 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/290602-ps-multiple-vs-industry-1-dark-2/1764067484400?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/290602-ps-multiple-vs-industry-1-dark-2/1764067484400"/></p>
<p>纳斯达克 GM:NAII 市销率与行业比较 2025 年 11 月 25 日</p>
<h3>Natural Alternatives International 的表现如何</h3>
<p>最近，Natural Alternatives International 的收入稳步上升，这令人欣慰。也许市场预计这种可接受的收入表现将会下滑，这使得市销率保持在低位。如果你喜欢这家公司，你会希望这种情况不会发生，这样你就可以在它不受欢迎时买入一些股票。</p>
<p>想要了解公司在收益、收入和现金流方面的全面情况吗？那么我们对 Natural Alternatives International 的 <strong>免费</strong> 报告将帮助你揭示其历史表现。</p>
<h2>收入增长指标告诉我们关于低市销率的什么？</h2>
<p>有一个内在的假设，即公司应该表现不及行业，才能使像 Natural Alternatives International 这样的市销率被视为合理。</p>
<p>回顾一下，我们看到公司去年收入增长了令人印象深刻的 19%。然而，这还不够，因为最近三年期间，公司总收入经历了 24% 的大幅下滑。因此，可以公平地说，最近的收入增长对公司来说并不理想。</p>
<p>将这一中期收入轨迹与更广泛行业一年的 5.0% 的扩张预测进行对比，显示出这并不乐观。</p>
<p>根据这些信息，我们并不感到惊讶，Natural Alternatives International 的市销率低于行业水平。然而，随着收入的下滑，市销率是否已经触底并没有保证。如果公司不改善其收入增长，市销率可能会进一步下降。</p>
<h2>最后的结论</h2>
<p>最新的股价飙升不足以将 Natural Alternatives International 的市销率拉近行业中位数。我们认为，市销率的作用主要不是作为估值工具，而是用来衡量当前投资者情绪和未来预期。</p>
<p>我们对 Natural Alternatives International 的审查确认，过去中期内公司收入的缩减是其低市销率的关键因素，因为行业预计将会增长。现在，股东们接受低市销率，因为他们承认未来的收入可能不会带来任何令人愉快的惊喜。如果最近的中期收入趋势持续下去，在这种情况下，很难看到股价在短期内有强劲的波动。</p>
<p>你需要注意风险，例如——<strong>Natural Alternatives International 有 3 个警告信号</strong>（还有 1 个让我们有点不安），我们认为你应该了解。</p>
<p>如果这些 <strong>风险让你重新考虑对 Natural Alternatives International 的看法</strong>，请查看我们互动式的高质量股票列表，以了解还有什么其他选择。</p>

Natural Alternatives国际

<p>Natural Alternatives International, Inc.（纳斯达克代码：NAII）的股价最近上涨了 35%，从之前的损失中恢复过来。尽管如此，该股票在过去一年中仍然下跌了 15%。公司的市销率低至 0.2 倍，显示出投资者的怀疑，因为其收入增长不稳定，去年增长了 19%，但在三年内下降了 24%。行业预测增长为 5%，突显了 NAII 的表现不佳。投资者持谨慎态度，接受低市销率是由于未来收入前景的不确定性</p>

<p><strong>Natural Alternatives International, Inc.</strong> (NASDAQ:NAII) shareholders would be excited to see that the share price has had a great month, posting a 35% gain and recovering from prior weakness. Unfortunately, the gains of the last month did little to right the losses of the last year with the stock still down 15% over that time.</p>
<div class="lb-trans"><p><strong>Natural Alternatives International, Inc.</strong>（纳斯达克代码：NAII）的股东们会很高兴地看到，股价在过去一个月表现出色，上涨了 35%，并从之前的疲软中恢复过来。不幸的是，过去一个月的涨幅对过去一年的损失几乎没有帮助，股票在此期间仍然下跌了 15%。</p>
</div><p>Even after such a large jump in price, it would still be understandable if you think Natural Alternatives International is a stock with good investment prospects with a price-to-sales ratios (or &#34;P/S&#34;) of 0.2x, considering almost half the companies in the United States' Personal Products industry have P/S ratios above 1x. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.</p>
<div class="lb-trans"><p>即使在如此大幅的价格上涨之后，如果你认为 Natural Alternatives International 是一只具有良好投资前景的股票，考虑到美国个人产品行业中几乎一半的公司市销率（&#34;P/S&#34;）超过 1 倍，市销率为 0.2 倍也是可以理解的。然而，我们需要更深入地探讨，以确定是否有合理的依据来解释较低的市销率。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即将改变医疗保健。这 20 只股票正在从早期诊断到药物发现等各个方面进行工作。最棒的是——它们的市值都在 100 亿美元以下——现在仍然有机会提前布局。</p>
</div><p>See our latest analysis for Natural Alternatives International</p>
<div class="lb-trans"><p>查看我们对 Natural Alternatives International 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/290602-ps-multiple-vs-industry-1-dark-2/1764067484400" alt="" original-src="https://images.simplywall.st/asset/chart/290602-ps-multiple-vs-industry-1-dark-2/1764067484400"/></p>
<p>NasdaqGM:NAII Price to Sales Ratio vs Industry November 25th 2025</p>
<div class="lb-trans"><p>纳斯达克 GM:NAII 市销率与行业比较 2025 年 11 月 25 日</p>
</div><h3>How Natural Alternatives International Has Been Performing</h3>
<div class="lb-trans"><h3>Natural Alternatives International 的表现如何</h3>
</div><p>Revenue has risen firmly for Natural Alternatives International recently, which is pleasing to see. Perhaps the market is expecting this acceptable revenue performance to take a dive, which has kept the P/S suppressed. If you like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.</p>
<div class="lb-trans"><p>最近，Natural Alternatives International 的收入稳步上升，这令人欣慰。也许市场预计这种可接受的收入表现将会下滑，这使得市销率保持在低位。如果你喜欢这家公司，你会希望这种情况不会发生，这样你就可以在它不受欢迎时买入一些股票。</p>
</div><p>Want the full picture on earnings, revenue and cash flow for the company? Then our <strong>free</strong> report on Natural Alternatives International will help you shine a light on its historical performance.</p>
<div class="lb-trans"><p>想要了解公司在收益、收入和现金流方面的全面情况吗？那么我们对 Natural Alternatives International 的 <strong>免费</strong> 报告将帮助你揭示其历史表现。</p>
</div><h2>What Are Revenue Growth Metrics Telling Us About The Low P/S?</h2>
<div class="lb-trans"><h2>收入增长指标告诉我们关于低市销率的什么？</h2>
</div><p>There's an inherent assumption that a company should underperform the industry for P/S ratios like Natural Alternatives International's to be considered reasonable.</p>
<div class="lb-trans"><p>有一个内在的假设，即公司应该表现不及行业，才能使像 Natural Alternatives International 这样的市销率被视为合理。</p>
</div><p>Taking a look back first, we see that the company grew revenue by an impressive 19% last year. However, this wasn't enough as the latest three year period has seen the company endure a nasty 24% drop in revenue in aggregate. Therefore, it's fair to say the revenue growth recently has been undesirable for the company.</p>
<div class="lb-trans"><p>回顾一下，我们看到公司去年收入增长了令人印象深刻的 19%。然而，这还不够，因为最近三年期间，公司总收入经历了 24% 的大幅下滑。因此，可以公平地说，最近的收入增长对公司来说并不理想。</p>
</div><p>Weighing that medium-term revenue trajectory against the broader industry's one-year forecast for expansion of 5.0% shows it's an unpleasant look.</p>
<div class="lb-trans"><p>将这一中期收入轨迹与更广泛行业一年的 5.0% 的扩张预测进行对比，显示出这并不乐观。</p>
</div><p>With this information, we are not surprised that Natural Alternatives International is trading at a P/S lower than the industry. Nonetheless, there's no guarantee the P/S has reached a floor yet with revenue going in reverse. There's potential for the P/S to fall to even lower levels if the company doesn't improve its top-line growth.</p>
<div class="lb-trans"><p>根据这些信息，我们并不感到惊讶，Natural Alternatives International 的市销率低于行业水平。然而，随着收入的下滑，市销率是否已经触底并没有保证。如果公司不改善其收入增长，市销率可能会进一步下降。</p>
</div><h2>The Final Word</h2>
<div class="lb-trans"><h2>最后的结论</h2>
</div><p>The latest share price surge wasn't enough to lift Natural Alternatives International's P/S close to the industry median. We'd say the price-to-sales ratio's power isn't primarily as a valuation instrument but rather to gauge current investor sentiment and future expectations.</p>
<div class="lb-trans"><p>最新的股价飙升不足以将 Natural Alternatives International 的市销率拉近行业中位数。我们认为，市销率的作用主要不是作为估值工具，而是用来衡量当前投资者情绪和未来预期。</p>
</div><p>Our examination of Natural Alternatives International confirms that the company's shrinking revenue over the past medium-term is a key factor in its low price-to-sales ratio, given the industry is projected to grow. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises either. If recent medium-term revenue trends continue, it's hard to see the share price moving strongly in either direction in the near future under these circumstances.</p>
<div class="lb-trans"><p>我们对 Natural Alternatives International 的审查确认，过去中期内公司收入的缩减是其低市销率的关键因素，因为行业预计将会增长。现在，股东们接受低市销率，因为他们承认未来的收入可能不会带来任何令人愉快的惊喜。如果最近的中期收入趋势持续下去，在这种情况下，很难看到股价在短期内有强劲的波动。</p>
</div><p>You need to take note of risks, for example - <strong>Natural Alternatives International has 3 warning signs</strong> (and 1 which makes us a bit uncomfortable) we think you should know about.</p>
<div class="lb-trans"><p>你需要注意风险，例如——<strong>Natural Alternatives International 有 3 个警告信号</strong>（还有 1 个让我们有点不安），我们认为你应该了解。</p>
</div><p>If these <strong>risks are making you reconsider your opinion on Natural Alternatives International</strong>, explore our interactive list of high quality stocks to get an idea of what else is out there.</p>
<div class="lb-trans"><p>如果这些 <strong>风险让你重新考虑对 Natural Alternatives International 的看法</strong>，请查看我们互动式的高质量股票列表，以了解还有什么其他选择。</p>
</div>

Natural Alternatives 国际公司（NASDAQ:NAII）的股价反弹了 35%，但其业务仍然落后于行业水平